Month: March 2026

– Fourth quarter revenue of $2.4 million, up 8.7% sequentially and 19.2% year-over-year TAMPA, Fla., March 27, 2026 (GLOBE NEWSWIRE) — LM Funding America, Inc. (NASDAQ: LMFA) (“LM Funding” or the “Company”), a Bitcoin treasury and mining company, today reported financial results for the three and twelve months ended December 31, 2025. Fourth Quarter 2025 Financial HighlightsTotal revenue for the fourth quarter ended December 31, 2025 was $2.4 million dollars, up 8.7% sequentially from Q3 2025 and 19.2% for the quarter year-over-year. The sequential increase reflects higher Bitcoin production but partial offset by a lower average Bitcoin price. The Company mined 22.0 Bitcoin during the fourth quarter 2025 at an average price of approximately $99,700, compared to 17.6 Bitcoin in Q3 2025 at an average Bitcoin value of approximately...

~ Q4 2025 Delivers Strongest Revenue Quarter of the Year ~ ~ Debt-Free Balance Sheet and $14M in Year-End Cash Enable Focus on Execution ~ ~ Diversified Revenue and Shift to Scalable Offerings Support Path to Profitable Future ~ SANTA MONICA, March 27, 2026 (GLOBE NEWSWIRE) —  Super League (Nasdaq: SLE) (the “Company”), an audience intelligence and media activation company that generates revenue by executing interactive advertising and immersive content programs for brands seeking to reach and influence people who play video games, today released fourth quarter and full year 2025 financial results. Super League Chief Executive Officer, Matt Edelman Commented: “Super League is a fundamentally different company than it was a year ago. We have a stronger foundation and a clearer path to scale, positioned to help brands reach and influence...

– Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year –  – Purchase commitment received for a minimum of $1.475 million for a clinical evaluation and outreach program in the Kingdom of Saudi Arabia – – Submitted of a Marketing Authorization Application with the Israel Ministry of Health – – U.S. Department of Defense authorized funding for procurement of bioengineered blood vessels – – Major milestone upcoming: Top-line interim result from V012 Phase 3 study in hemodialysis access – – Conference call today at 8:00 am ET – DURHAM, N.C., March 27, 2026 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered...

Company continues to evaluate strategic options to maximize shareholder value WATERTOWN, Mass., March 27, 2026 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2025. “We have initiated a process to explore a range of alternatives available to the Company to maximize stockholder value,” said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf. “Such measures may include, among other options, a sale of the Company, a business combination...

AUCATZYL® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025 AUCATZYL® UK launch underway following successful National Institute for Health and Care Excellence (NICE) evaluation Autolus continues to expect full year 2026 AUCATZYL® net product revenue of $120 million to $135 million and shift to positive gross margin to occur in 2026 Independent real-world AUCATZYL® data from ROCCA consortium confirm high level of clinical activity with favorable safety profile Pivotal Phase 2 clinical trials with obe-cel in ​lupus nephritis and pediatric ALL enrolling; initial clinical data from BOBCAT Phase 1 trial in progressive MS anticipated by year-end 2026 Conference call to be held today at 08:30 am EDT/12:30 pm GMT: conference call participants should pre-register...

Record Quarterly Revenues of $737.6 Million, a 34.6% Increase from a Year Ago Quarterly Adjusted EBITDA (non-GAAP) Increased 53% from Prior Year1 Record Total Backlog and Awards of $3.7 Billion, 49% Increase from a Year Ago, with Robust Q4 Book-to-Bill of 1.9x Tuck-In Acquisition of Seattle Area-Based Engineering Firm Establish First Quarter 2026 Guidance for Revenue of $925 Million – $950 Million and Non-GAAP Adjusted EBITDA of $90 Million – $100 Million Raise Full Year 2026 Guidance for Revenue to $3.7 Billion – $3.9 Billion and Non-GAAP Adjusted EBITDA of $400 Million – $430 Million SAN JOSE, Calif., March 27, 2026 (GLOBE NEWSWIRE) — Legence Corp. (Nasdaq: LGN) (“Legence” or the “Company”) today reported financial results for the fourth quarter and year ended December 31, 2025. “Our fourth quarter 2025...